We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
For investors seeking momentum, ARK Innovation ETF (ARKK - Free Report) is probably on the radar. The fund just hit a 52-week high and is up about 92.4% from its 52-week low price of $36.85/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:
ARKK in Focus
ARK Innovation ETF provides thematic multi-cap exposure to “disruptive innovation.” It is an actively managed fund investing in companies that benefit from the development of new products or services, technological improvements and advancements in scientific research related to the areas of DNA technologies and genomic revolution, automation, robotics, energy storage, artificial intelligence, next-generation Internet and Fintech innovation. ARKK charges 75 bps in annual fees (see: all the Broad Developed World ETFs here).
Why the Move?
This ETF has been an area to watch lately, given Cathie Wood’s, the high-profile CEO of Ark Investment Management, explosive moves in a few stock holdings of ARKK. Cathie Wood continued its active bets on disruptive innovation by purchasing shares of CRISPR Therapeutics AG (CRSP - Free Report) and selling 908 Devices Inc. (MASS - Free Report) and Roku Inc. (ROKU - Free Report) . This move reinforces ARK’s long-standing bullish stance on gene-editing technologies. ARK also bought a few shares of Beam Therapeutics Inc. (BEAM - Free Report) , reflecting evolving conviction in the future of biotech innovation.
Cathie Wood remains bullish on the transformative power of emerging technologies despite the market turbulence.
Image: Bigstock
Innovation ETF (ARKK) Hits New 52-Week High
For investors seeking momentum, ARK Innovation ETF (ARKK - Free Report) is probably on the radar. The fund just hit a 52-week high and is up about 92.4% from its 52-week low price of $36.85/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:
ARKK in Focus
ARK Innovation ETF provides thematic multi-cap exposure to “disruptive innovation.” It is an actively managed fund investing in companies that benefit from the development of new products or services, technological improvements and advancements in scientific research related to the areas of DNA technologies and genomic revolution, automation, robotics, energy storage, artificial intelligence, next-generation Internet and Fintech innovation. ARKK charges 75 bps in annual fees (see: all the Broad Developed World ETFs here).
Why the Move?
This ETF has been an area to watch lately, given Cathie Wood’s, the high-profile CEO of Ark Investment Management, explosive moves in a few stock holdings of ARKK. Cathie Wood continued its active bets on disruptive innovation by purchasing shares of CRISPR Therapeutics AG (CRSP - Free Report) and selling 908 Devices Inc. (MASS - Free Report) and Roku Inc. (ROKU - Free Report) . This move reinforces ARK’s long-standing bullish stance on gene-editing technologies. ARK also bought a few shares of Beam Therapeutics Inc. (BEAM - Free Report) , reflecting evolving conviction in the future of biotech innovation.
Cathie Wood remains bullish on the transformative power of emerging technologies despite the market turbulence.
More Gains Ahead?
ARKK might remain strong going ahead, given a weighted alpha of 60.23 and a higher 20-day volatility of 29.55%. There is definitely some promise for investors who want to ride on this surging ETF.